NCT06299891View on ClinicalTrials.gov

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Hypothalamic ObesityHypothalamic TumorCraniopharyngioma
Interventions
DRUG

Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]

To assess safety and maximum tolerated dose as well as efficacy on weight loss of Phentermine/Topiramate in individuals with hypothalamic obesity.

OTHER

Placebo

To assess safety and maximum tolerated dose as well as efficacy on weight loss of placebo treatment in individuals with hypothalamic obesity.

Trial Locations (2)

19104

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

98101

RECRUITING

Seattle Children's, Seattle

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

lead

Seattle Children's Hospital

OTHER